The first generic GLP-1 receptor agonist, liraglutide 1.8 mg, has been launched in the U.S. by Teva Pharmaceuticals. This medication is indicated for improving glycemic control in patients with type 2 diabetes and reducing the risk of cardiovascular events in certain patients. The brand-name version of this medication had annual sales of $1.656 billion. Common adverse effects include nausea, diarrhea, vomiting, and decreased appetite, while serious adverse effects may include pancreatitis, hypoglycemia, and thyroid tumors. This launch provides another treatment option for patients with type 2 diabetes and strengthens Teva’s complex generics portfolio.
Source link
First generic GLP-1 receptor agonist launched
